RC148

RC148 is a humanized IgG1 silenced bispecific antibody targeting VEGF and PD-1. RC148 allows dimeric VEGF crosslinking and gradually enhances PD-1 binding activity, potentially reduces systemic toxicity of the anti-VEGF approach, and enhances antitumor potency via VEGF-triggered enrichment in tumor areas. RC148 blocks the binding of VEGF to VEGFR and PD-1 to PD-L1, prevents the growth and migration of human umbilical vein endothelial cells, and enables efficient T cell activation. RC148 can be used for the study of breast cancer and lung cancer[1].

12352005

PD-1/PD-L1; VEGFR

Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Cancer

[1]Jianmin Fang, et al. RC148, a novel bispecific antibody targeting PD-1 and VEGF for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA) : AACR; Cancer Res 2024;84 (6_Suppl) :Abstract nr 2734.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991739/

Inhibitory Antibodies

No Development Reported